(Q57452831)

English

Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer

scientific article published on 17 October 2018

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

anaplastic thyroid cancer

1 reference

based on heuristic

inferred from title

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Gordon J. Freeman

8

object named as

Gordon J Freeman

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

author name string

Viswanath Gunda

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Benjamin Gigliotti

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Dorothy Ndishabandi

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Tameem Ashry

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Michael McCarthy

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Zhiheng Zhou

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Salma Amin

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Alessandro Alessandrini

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

language of work or name

0 references

publication date

17 October 2018

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

119

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

1223-1232

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Biologic and Clinical Perspectives on Thyroid Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Anaplastic thyroid cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Genomic complexity and targeted genes in anaplastic thyroid cancer cell lines.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeted Therapy in Thyroid Cancer: State of the Art.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolving molecularly targeted therapies for advanced-stage thyroid cancers

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Leveraging the immune system to treat advanced thyroid cancers

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer immunotherapies targeting the PD-1 signaling pathway

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Learning from PD-1 Resistance: New Combination Strategies.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-Invasive Monitoring of CNS MHC-I Molecules in Ischemic Stroke Mice

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of subcutaneous tumor size in athymic (nude) mice

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Functions of natural killer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunosuppression involving increased myeloid-derived suppressor cell levels, systemic inflammation and hypoalbuminemia are present in patients with anaplastic thyroid cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comprehensive screening for PD-L1 expression in thyroid cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulatory T-cell heterogeneity and the cancer immune response

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumour-associated macrophages as treatment targets in oncology.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0296-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effector cell expression of NK1.1, a murine natural killer cell-specific molecule, and ability of mice to reject bone marrow allografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/30327563

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30327563

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/S41416-018-0296-2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30327563%20AND%20SRC:MED&resulttype=core&format=json

29 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57452831&oldid=2175433775"